Phenytoin in Topical Formulations Augments Pain Reduction of Other Analgesics in the Treatment of Neuropathic Pain

David J Kopsky* and Jan M Keppel Hesselink

Institute for Neuropathic Pain, Bosch en Duin, The Netherlands

*Corresponding author: David J Kopsky, MD, Institute for Neuropathic Pain, Vespuccistraat 64-III, 1056 SN, Amsterdam, The Netherlands, Tel: +31-6-28671847, E-mail: info@neuropathie.nu

Abstract

Topical analgesic formulations are gaining interest for the treatment of peripheral neuropathic pain since the beginning of 2000. Advantages of topical analgesics over oral medication are the absence of systemic side effects and drug-drug interactions, higher concentrations of active compound at the pain area, fast onset on action, improvement of compliance, and no risk of abuse. In many peripheral neuropathic pain states the pain area is small and thus topical analgesics are suitable. Most patients experience pain reducing effect within 30 minutes after application of compounded topical analgesics, such as creams containing amitriptyline, ketamine, baclofen, or clonidine. This helps to quickly identify responders on selected analgesic creams.

Unfortunately, in some patients the duration of topically applied analgesic formulations is short and/or the reduction of pain is insufficient. Therefore, strategies to prolong the duration and intensify the analgesic effect are needed. We discovered that phenytoin augments the effects of topical analgesics, leading to a faster onset of action, a longer duration of analgesia, and an intensified pain relieving effect. We will present 6 cases in which phenytoin 5% or 10% lead to enhanced therapeutic effects of topical applied amitriptyline 10%, ketamine 10%, baclofen 5%, or clonidine 0.2% creams in the treatment of neuropathic pain. We also present a fast topical analgesic response-test to identify responders within a 30 minutes’ assessment period after a test application. A responder is defined as experiencing at least 2 points reduction of pain intensity, as measured with the 11-point numerical rating scale (NRS).

Introduction

Since 2000 topical analgesics have been gaining interest for the treatment of peripheral neuropathic pain. This is most probably due to the fact that topical analgesics have a number of advantages over oral medication, such as the absence of systemic side effects and drug-drug interactions, fast onset of pain relief, high concentration of the active compound at the application area, improvement of compliance, and no risk of abuse [1]. These advantages are based on the fact that topical analgesics have a peripheral mechanism of action, without the need to enter the bloodstream. Especially in geriatric patients with neuropathic pain, with high risk of undesirable side effects, drug-drug interactions and/or altered metabolization due to intake of multiple medications, topical analgesics should be considered as a first line treatment option [2].

In our Institute for Neuropathic Pain we developed and tested topical compounded analgesics, such as ketamine 10%, amitriptyline 10%, and baclofen 5% creams [3-10]. Most responders experience pain reducing effect within 30 minutes after application. Using a topical analgesic response-test, responders can be identified within a 30 minutes assessment period after a test application. A responder is defined as least 2 points reduction of pain intensity, as measured with the 11-point numerical rating scale (NRS). After identifying the responder as such, we prescribc the topical analgesic which was tested.

Unfortunately, some of our patients experience pain relief only for a short period of time (e.g. 1 to 2 hours). In our search to solve this problem we discovered that the old anticonvulsant phenytoin has remarkable properties. Phenytoin added to other active compounds in topical formulations leads to augmentation of effects, such as a faster onset of action, a longer duration of
analgesia, and/or an intensified pain relieving effect. Topical phenytoin is currently only known to accelerate healing of chronic ulcers and wounds [11, 12]. In the present study 6 cases in which phenytoin is added as a booster to an analgesic in a topical formulation in patients suffering from a variety of neuropathic pain syndromes are presented.

Case Presentations

Case 1: Small fiber neuropathy (SFN)

A 57-year-old man suffered from symptoms of SFN, being treated with pregabalin, without sufficient pain reduction. The patient complained of burning pain, tingling and coldness in feet and hands, aggravating while standing and walking. One part of the neuropathic pain area (situated at the most painful foot) was treated with ketamine 10% cream. This resulted after 10 minutes in a slight reduction of burning pain, although the tingling aggravated. Another not yet treated part of the most painful foot was subsequently treated with phenytoin 10% cream. This resulted within a timeframe of 10 minutes in a reduction of burning pain as well as of coldness. Adding phenytoin cream on top of the ketamine cream resulted within 5 minutes in a further pain reduction from 6.5 to 3 on the NRS. Surprisingly, the aggravated tingling provoked by ketamine cream disappeared totally after the application of the phenytoin cream. The overall finding was expressed by the patient as: “it all feels now peaceful and quit in the area where the two creams were applied”. The improvement lasted for 24 hours.

Case 2: Diabetic neuropathic pain

A 69-year-old man suffered since 2007 from diabetic neuropathic pain in both forefeet and scored the pain as 9 on the NRS. The pain was characterized by burning, electric shocks, tingling, pins and needles, allodynia (pain in response to normally non-painful stimuli) after soft stroking. Especially the allodynia in his left foot was bothering him during night. Pregabalin 75 mg twice daily did not have any effect. Administering ketamine 10% cream [8], resulted in pain reduction from 9 to 5.5 on the NRS, with an onset of effect of 25 minutes and duration of pain reduction of 6.5 hours. Adding phenytoin 10% on top of ketamine 10% cream resulted in an onset of effect of around 5 minutes, reduction of pain to 2.5 on the NRS, and a prolonged duration of effect of 11 hours.

Case 3: Chronic idiopathic axonal polyneuropathy (CIAP)

A 63-year-old man suffered since 2012 of CIAP with pain in both feet (8 on the NRS) with the following characteristics: burning, pins and needles and numbness. Oral amitriptyline did not have any pain relieving effect. Topical clonidine 0.2% cream reduced symptoms after 15 minutes: the sensation of pins and needles is reduced to 5 and the burning pain to 2.5 on the NRS. The duration of the effect was 6 hours only, resulting in disrupt-ed sleep. After adding phenytoin 5% to clonidine 0.2% cream, the onset of effect was within 5 minutes, the sensation of pins and needles was more reduced to a score of 2.5, and burning pain to a score of 0 on the NRS. The duration of the effect was 10 hours; thus, he could sleep the whole night through. He also could reduce the application of cream from 3 to 2 times daily after phenytoin was added.

Case 4: Chemotherapy induced Polyneuropathy (CIPN)

A 67-year-old man suffered since 2015 of CIPN a developed during the treatment with oxaliplatin of a metastasized rectal carcinoma. He experienced his pain as tingling, pins and needles and numbness in both feet and complained of coldness of the feet. He scored his complaints as 5 on the NRS. The combination cream of lidocaine 3% together with isosorbide dinitrate 0.4% cream reduced his pain to a 4 on the NRS. To check the difference in effect between phenytoin 10% cream, compared to the combination of phenytoin 10% and baclofen 5% cream, phenytoin 10% cream was applied on the left foot, and the combination cream was applied on the right foot. He experienced pain reduction of the left foot from 4 to 3 and the right foot from 4 to 1 on the NRS. The booster phenytoin 10% cream applied alone had only a slight symptom reducing effect, while in combination with baclofen 5% cream a clear symptom reduction was seen.

Case 5: CIPN

A 48-year-old man suffering from acute leukemia was treated with mitoxantrone and etoposide in July 2014. The chemotherapy caused hand-foot syndrome (redness and edema), and neuropathic pain in the feet. He described the pain as burning, tingling, pins and needles, and scored this pain with an 8.5 on the NRS in November 2015. Physical examination revealed hypoesthesia for pinprick and touch, and allodynia. Amitriptyline 10% cream reduced within 8 minutes the pain to a score of 0 on the NRS, though only for 1 to 1.5 hours. In October 2016, he scored the neuropathic pain as 6 on the NRS. He was subsequently treated with phenytoin 5% cream, which also resulted in complete disappearance of the neuropathic pain, though the duration was clearly longer: 3.5 hours, with an onset of effect of 15 minutes after application. The combination of phenytoin 5% and amitriptyline 10% resulted in complete disappearance of the pain, with a prolonged effect of in total 8 hours and an onset of action of 3 minutes. He could sleep again the whole night without being disturbed.

Case 6: Neuropathic pain after Guillain-Barre syndrome

A 63-year-old man suffered from Guillain-Barre syndrome in 1980. He recovered with minor sequelae: numbness of the feet, reduced facial expressions, and diminished motor function of the left hand. In 2011 he experienced stabbing pain in his big left toe (8.5 on the
NRS) especially at night. Oral pregabalin had some pain reducing effect, but he experienced bothersome side effects: anxiety and depression. Baclofen 5% cream clearly reduced the pain completely, but had to be applied 2 to 4 times during the night. Adding phenytoin 5% to baclofen 5% cream prolonged the pain reducing effect considerably and only one application before sleeping was required.

None of the above described patients reported any local or systemic side effects, the creams were well tolerated and administration was conducted without problems.

Discussion

Recently, we reported that phenytoin could augment the effects of ketamine 10% and baclofen 5% in trigeminal neuralgia [13]. Adding phenytoin to analgesics or co-analgesics in a topical formulation, led to 1) faster onset of action, 2) longer duration of analgesia, and 3) more pronounced analgesia in neuropathic pain. The mechanisms of action of phenytoin are pleiotropic, related to a number of ion channels and other targets, and thus synergistic effects when combined with the analgesics described below are to be expected. Phenytoin is well-known as a non-selective voltage-gated sodium channel (Na_h) stabilizer [14]. Furthermore, phenytoin inhibits voltage dependent L-type calcium channels [15], and influences the GABA receptor [16]. However, the full spectrum of phenytoin’s mechanism of action is still unfolding.

An intact nociceptor function in the epidermis is essential to achieve analgesia with topical analgesics. Campell, et al. examined this phenomenon in a randomized controlled trial in patients suffering from painful diabetic neuropathy [17]. The effectiveness of topical clonidine 0.1% in reducing pain is dependent on the severity or intensity of pain measured 30 minutes after capsaicin 0.1% application.

Faster onset of action

The faster onset of action after adding phenytoin to an analgesic cream, is most probably due to a synergistic effect of phenytoin and the other active compound. As described in case 2, amitriptyline and ketamine applied separately led to an onset of action within 10 to 15 minutes, while combining either amitriptyline or ketamine with phenytoin led to an onset of action of less than 5 minutes. A fast onset of effect of topical analgesics in literature, is only sparsely described. To our knowledge, only one publication showed that a combination of compounds showed a faster onset of action than the single compounds. In a patent from 1997 a faster onset of action was described after topical application of the combination ketamine and amitriptyline, compared to the topical single compounds [18]. A topical analgesic has to penetrate the lipophilic stratum corneum, which is around 0.02 mm thick [19], in order to reach the nociceptive nerve endings located in the stratum spinosum. The lipophilic nature of phenytoin, the small size of the molecule (252 Dalton), the selected high concentration (10%), and the presence of penetration enhancers in the topical formulation might explain the fast onset of effect.

The fast onset of action by adding phenytoin to another analgesic in a topical formulation, could also reside in the fact that phenytoin might influence epidermal keratinocytes, which on their turn can influence the nociceptors reaching up to the upper layers of the stratum spinosum [20]. Na_h on epidermal keratinocytes in pain syndromes are upregulated [21], and activation results in ATP release leading to activation of P2X receptors on nociceptive sensory endings. Phenytoin as a Na_h stabilizer can thus stabilize the upregulated Na_h of keratinocytes in pain syndromes [14,22].

The fast onset of action further suggests a role of peripheral sensitization in these pain syndromes. Although central sensitization can be influenced with topical analgesics [23], in that case one might expect the onset of effect to be longer than described in our cases.

Longer duration of analgesia

The mechanism of the prolonged pain reduction when adding phenytoin to a topical formulation with ketamine, baclofen or clonidine is not known. From other compounds used as adjuvants it is known that these prolonged effects of local anesthetics. For example, prolongation of pain reducing effect is observed when using magnesium sulfate as an adjuvant to local anesthetics in perineural nerve blocks [24]; in neuraxial blocks the adjuvant dexmedetomidine to local anesthetics prolongs the duration of analgesia [25].

More pronounced analgesia

The use of multiple oral analgesics from different classes gives a more pronounced pain reduction compared to single oral analgesics [26-29]. Also there is some evidence that combinations of topical (co)analgesics lead to a more pronounced pain reduction compared to topical monotherapy [30-32]. Influencing multiple receptors and/or enhancing affinities of the main analgesic compounds might be the explanation for pronounced pain reduction.

In conclusion, phenytoin seems to augment other analgesic compounds when added to topical formulations. Its broad receptor and ion channel affinity might explain the synergistic effects we found when combining phenytoin with analgesic compounds. Our patients have not reported any side effects in the treatment of neuropathic pain, when treated with the combination of topical phenytoin and other analgesic compounds. Topical analgesics have several advantages over oral analgesics, such as the absence of systemic side effects,
low propensity for drug-drug interactions, while leading to higher concentrations of active compound at the pain area, a fast onset of pain relief, improvement of compliance, and no risk of abuse. We recommend to perform a response-test before prescribing a topical analgesic, in order to optimize the treatment.

Conflict of Interest

The authors are holders of two patents: 1) Topical phenytoin for use in the treatment of peripheral neuropathic pain and 2) Topical pharmaceutical composition containing phenytoin and a (co-)analgesic for the treatment of chronic pain. The authors report no other conflicts of interest in this work.

References